Chapter 5: Autonomic Adrenergic Pharmacology — Module 4: Indirect-Acting and Mixed Adrenergic Agonists, Adrenergic Neuron Blockers, and Drug Interactions Core Concepts: Foundational Knowledge (12 Questions)
BEFORE YOU BEGIN
Modules 1 through 3 established the receptor framework and covered drugs that act directly on adrenergic receptors. Module 4 introduces a mechanistically distinct group: drugs that produce their adrenergic effects indirectly — by releasing, preserving, or augmenting endogenous norepinephrine (NE) rather than binding receptors themselves. This distinction matters enormously in clinical practice. Indirect-acting drugs depend on NE stores — deplete those stores and they lose efficacy. They are subject to tachyphylaxis in ways that direct agonists are not. Their interactions with other drugs (MAOIs, tricyclic antidepressants, reserpine) can be life-threatening. And they include some of the most clinically significant substances encountered in medicine — cocaine, amphetamines, ephedrine — as well as the historically important adrenergic neuron blockers. The tyramine reaction, one of the most dangerous drug-food interactions in clinical pharmacology, is explained entirely by the principles in this module. Work carefully through these questions — they connect basic pharmacology to real clinical hazards.
1. Indirect-acting sympathomimetics produce adrenergic effects without directly binding adrenergic receptors. Which of the following correctly describes the primary mechanism by which indirect-acting sympathomimetics increase synaptic norepinephrine (NE) concentration?
A) Indirect-acting sympathomimetics act by inhibiting monoamine oxidase (MAO) in the nerve terminal, preventing the intraneuronal degradation of NE; the preserved NE accumulates in the cytoplasm and is released in greater amounts per action potential, producing enhanced sympathomimetic effects
B) Indirect-acting sympathomimetics enter the presynaptic nerve terminal via the norepinephrine transporter (NET — the reuptake carrier) and displace NE from synaptic vesicles into the cytoplasm; the cytoplasmic NE is then transported out of the nerve terminal into the synapse via reverse transport through NET, releasing NE into the synaptic cleft independent of neuronal firing or calcium-dependent exocytosis
C) Indirect-acting sympathomimetics bind to presynaptic alpha-2 autoreceptors as antagonists, blocking the negative feedback loop that normally limits NE release; by removing the inhibitory autoreceptor brake, they allow unchecked NE release with each action potential, producing amplified sympathomimetic effects
D) Indirect-acting sympathomimetics block the vesicular monoamine transporter (VMAT2 — the transporter that packages NE into synaptic vesicles) without entering the nerve terminal, preventing NE from being repackaged after release; the unpackaged NE remains in the synaptic cleft for longer than normal, producing prolonged sympathomimetic effects
E) Indirect-acting sympathomimetics directly stimulate the release of NE from the adrenal medulla by activating nicotinic receptors on chromaffin cells, producing a systemic surge of circulating NE that activates peripheral adrenergic receptors throughout the body
ANSWER: B
Rationale:
The defining mechanism of indirect-acting sympathomimetics such as amphetamine, ephedrine, and tyramine is entry into the presynaptic nerve terminal via the norepinephrine transporter (NET) and subsequent displacement of NE from synaptic vesicles. Once inside the terminal, these drugs enter synaptic vesicles via VMAT2 (vesicular monoamine transporter 2) and exchange for NE, releasing NE into the cytoplasm. The cytoplasmic NE is then transported outward through NET operating in reverse (reverse transport) — releasing NE into the synaptic cleft without requiring action potential firing or calcium-dependent vesicular exocytosis. This explains a critical pharmacological property: indirect-acting sympathomimetics can release NE even when neuronal firing is blocked (e.g., in the presence of tetrodotoxin or local anesthetics), because their mechanism bypasses calcium-dependent vesicle fusion entirely. The magnitude of their effect depends entirely on the availability of NE stores in the nerve terminal — deplete those stores (with reserpine, which blocks VMAT2 and prevents vesicular NE packaging) and indirect agonists lose their efficacy.
Option A: Option A describes MAO inhibition, which is a separate mechanism. While MAO inhibitors do increase synaptic NE by preventing its intraneuronal degradation, this is not the primary mechanism of indirect-acting sympathomimetics such as amphetamine; their primary mechanism is vesicular NE displacement and reverse NET transport.
Option C: Option C describes presynaptic alpha-2 autoreceptor antagonism — the mechanism of drugs like yohimbine. This increases NE release per action potential but is not the mechanism of classical indirect-acting sympathomimetics such as amphetamine, ephedrine, and tyramine.
Option D: Option D incorrectly describes a peripheral VMAT2 blocking mechanism without entry into the nerve terminal. Reserpine (not indirect agonists) blocks VMAT2 from inside the terminal; the description of prolonged synaptic cleft NE is not the indirect agonist mechanism.
Option E: Option E incorrectly attributes the mechanism to adrenal medulla stimulation via nicotinic receptors. While the adrenal medulla does have nicotinic receptors and catecholamines are released from it, this is not the mechanism by which indirect-acting sympathomimetics increase synaptic NE.
2. Cocaine produces sympathomimetic effects through a mechanism that differs from amphetamine despite both increasing synaptic NE. Which of the following correctly distinguishes cocaine's mechanism from that of amphetamine?
A) Cocaine and amphetamine use identical mechanisms — both enter the presynaptic nerve terminal via NET and displace NE from synaptic vesicles; cocaine is simply a more potent version of amphetamine at equivalent doses; the clinical difference between them reflects pharmacokinetic rather than pharmacodynamic differences
B) Cocaine acts by inhibiting MAO in the presynaptic terminal, preventing NE degradation and increasing the amount available for release; amphetamine blocks NET at the terminal membrane, preventing NE reuptake after release; both increase synaptic NE but at different points in its lifecycle
C) Cocaine acts by blocking adrenergic receptors postsynaptically, preventing NE from producing its normal effect and triggering a compensatory increase in NE release through loss of autoreceptor feedback; amphetamine produces direct receptor activation without affecting NE concentrations
D) Cocaine blocks NET (the norepinephrine transporter) at the presynaptic membrane, preventing the reuptake of released NE from the synaptic cleft — synaptic NE accumulates because its removal is impaired; amphetamine enters the terminal via NET and causes active release of NE from vesicles through reverse transport — NE is pushed into the cleft even without neuronal firing; the key distinction: cocaine requires prior NE release to have occurred (it prolongs the effect of released NE), while amphetamine can release NE independently of neuronal activity
E) Cocaine is a direct-acting adrenergic agonist that mimics NE at alpha and beta receptors; its sympathomimetic effects do not involve NE at all; amphetamine is an indirect agonist that works through NE release; this is why cocaine's effects persist after NE store depletion but amphetamine's do not
ANSWER: D
Rationale:
The mechanistic distinction between cocaine and amphetamine is one of the most pharmacologically important comparisons in adrenergic pharmacology. Cocaine is a reuptake inhibitor — it blocks NET at the presynaptic membrane, preventing the reuptake of NE that has already been released into the synapse; synaptic NE accumulates because its clearance is blocked, prolonging and intensifying the effect of each NE release event. Importantly, cocaine requires that NE has first been released by the nerve terminal — it only prolongs what is already there. Amphetamine is an active releaser — it enters the terminal via NET, displaces NE from vesicles, and drives NE outward through reverse NET transport independent of neuronal firing or calcium-dependent exocytosis. This distinction has a critical pharmacological test: after NE store depletion with reserpine, cocaine retains some efficacy (because some NE can still be released and cocaine prolongs its effect) while amphetamine loses most of its efficacy (because there is no stored NE left to release). Cocaine also blocks the dopamine transporter (DAT) and serotonin transporter (SERT), contributing to its CNS stimulant and abuse properties.
Option A: Option A incorrectly states that cocaine and amphetamine use identical mechanisms. Their mechanisms differ fundamentally — cocaine blocks reuptake at the membrane while amphetamine causes active release from vesicles.
Option B: Option B incorrectly assigns MAO inhibition to cocaine and NET blockade to amphetamine. Cocaine's primary mechanism is NET blockade (reuptake inhibition), not MAO inhibition; amphetamine's mechanism is reverse transport/NE release, not simple NET blockade.
Option C: Option C incorrectly describes cocaine as a postsynaptic adrenergic receptor blocker. Cocaine does not block adrenergic receptors; it is a NET reuptake inhibitor. Additionally, amphetamine is not a direct receptor agonist.
Option E: Option E incorrectly describes cocaine as a direct-acting adrenergic agonist. Cocaine is an indirect sympathomimetic that works by blocking NE reuptake; it does not directly bind adrenergic receptors. The statement about cocaine's persistence after NE depletion is partially true but the mechanism description is wrong.
3. Ephedrine is classified as a mixed-acting sympathomimetic. Which of the following correctly explains what "mixed-acting" means for ephedrine and identifies the clinical implication of this mixed mechanism?
A) Ephedrine has both direct adrenergic receptor agonist activity (it can bind and activate alpha-1 and beta receptors directly) and indirect activity (it enters presynaptic nerve terminals and releases NE through reverse transport); because it has both components, ephedrine retains partial efficacy after NE store depletion (through direct receptor activation) but its full effect requires intact NE stores; tachyphylaxis with repeated dosing reflects progressive depletion of the NE store available for the indirect component, reducing efficacy even as the direct component persists
B) Ephedrine is mixed-acting because it acts on both alpha and beta adrenergic receptors simultaneously; its alpha-1 activation produces vasoconstriction while its beta-2 activation produces bronchodilation; "mixed" refers to receptor subtype breadth rather than mechanism of action; ephedrine has no indirect component and does not affect presynaptic NE stores
C) Ephedrine is mixed-acting because it functions as an agonist at some adrenergic receptors and an antagonist at others; it activates beta-2 receptors (producing bronchodilation) while blocking alpha-1 receptors (preventing vasoconstriction); this dual agonist-antagonist profile explains its use in asthma without the hypertensive side effects of pure alpha-1 agonists
D) Ephedrine is mixed-acting because it has both adrenergic and cholinergic activity; its adrenergic component produces sympathomimetic effects while its cholinergic component activates muscarinic receptors in the airway to produce bronchodilation through a parasympathomimetic mechanism; this dual autonomic profile is unique to ephedrine among sympathomimetics
E) Ephedrine is mixed-acting because it is a prodrug that is partially converted to epinephrine in the liver; the parent compound (ephedrine) acts directly on beta-2 receptors while the active metabolite (epinephrine) acts indirectly through NE store release; "mixed" refers to the parent compound versus metabolite activity rather than a single molecule having two mechanisms
ANSWER: A
Rationale:
"Mixed-acting" describes a drug that produces sympathomimetic effects through both direct receptor activation and indirect NE release. Ephedrine has modest direct agonist activity at alpha-1, beta-1, and beta-2 adrenergic receptors, and also enters presynaptic nerve terminals to displace NE from vesicles and release it through reverse NET transport — the same indirect mechanism used by amphetamine and tyramine. The clinical consequence of this dual mechanism is nuanced and important: (1) Partial persistence of effect after NE depletion — because the direct component remains operative even when NE stores are depleted, ephedrine retains some efficacy (unlike pure indirect agonists like tyramine); (2) Tachyphylaxis with repeated dosing — repeated ephedrine doses progressively deplete the NE pool available for indirect release; each subsequent dose produces a smaller indirect component, and since the direct component is modest, overall efficacy declines; this tachyphylaxis is particularly important in anesthesia, where ephedrine is used to treat intraoperative hypotension and repeated doses may become less effective.
Option B: Option B incorrectly defines "mixed-acting" as receptor subtype breadth (alpha and beta activity) rather than mechanism of action (direct plus indirect). Many direct-acting sympathomimetics activate both alpha and beta receptors; receptor breadth alone does not constitute "mixed-acting."
Option C: Option C incorrectly describes ephedrine as having antagonist activity at alpha-1 receptors. Ephedrine activates alpha-1 receptors (contributing to its vasopressor effect); it does not block them.
Option D: Option D incorrectly attributes cholinergic activity and muscarinic receptor activation to ephedrine. Ephedrine has no cholinergic activity; its bronchodilatory effect is through beta-2 adrenergic receptor activation, not parasympathomimetic muscarinic stimulation.
Option E: Option E incorrectly describes ephedrine as a prodrug converted to epinephrine. Ephedrine is not metabolically converted to epinephrine; it is itself an active drug with direct and indirect adrenergic activity as a single molecular entity.
4. Reserpine is an adrenergic neuron blocker that was used as an antihypertensive before being largely replaced by better-tolerated agents. Which of the following correctly identifies reserpine's mechanism of action and explains how it reduces blood pressure?
A) Reserpine blocks the release of NE from sympathetic nerve terminals by inhibiting voltage-gated calcium channels at the nerve terminal membrane, preventing calcium-dependent vesicular exocytosis; without calcium influx, NE vesicle fusion cannot occur and NE release is abolished; blood pressure falls because peripheral sympathetic tone is eliminated
B) Reserpine blocks alpha-1 adrenergic receptors postsynaptically on vascular smooth muscle, preventing NE from activating the Gq/PLC/calcium cascade that produces vasoconstriction; blood pressure falls because the vasoconstrictor signal is blocked at the receptor level regardless of how much NE is released
C) Reserpine inhibits tyrosine hydroxylase — the rate-limiting enzyme in the catecholamine biosynthetic pathway — preventing the conversion of tyrosine to DOPA and thereby depleting NE stores through failure of synthesis; blood pressure falls as NE stores progressively decline over days to weeks
D) Reserpine blocks alpha-2 presynaptic autoreceptors, removing the negative feedback inhibition of NE release and paradoxically increasing NE release; the resulting NE surge initially raises blood pressure, followed by receptor desensitization and downregulation that produces sustained hypotension
E) Reserpine irreversibly blocks VMAT2 (vesicular monoamine transporter 2) — the transporter responsible for packaging NE (and dopamine, serotonin) into synaptic vesicles; without VMAT2 function, newly synthesized NE cannot be stored in vesicles and is degraded by intraneuronal MAO; existing vesicular NE is gradually released but not replaced; NE stores become progressively depleted over days, sympathetic tone falls, and blood pressure decreases; the irreversibility of VMAT2 blockade means recovery requires synthesis of new VMAT2 protein
ANSWER: E
Rationale:
Reserpine's antihypertensive mechanism is irreversible blockade of VMAT2 (vesicular monoamine transporter 2) — the transporter that packages monoamines (NE, dopamine, serotonin) from the cytoplasm into synaptic vesicles for storage and calcium-dependent release. When VMAT2 is irreversibly blocked, newly synthesized NE cannot be packaged into vesicles and is instead degraded by intraneuronal MAO before it can accumulate. Existing vesicular NE is gradually released through normal nerve activity but is not replaced. Over days, vesicular NE stores become progressively depleted; sympathetic neurotransmission fails as there is no packaged NE to release; peripheral vascular resistance falls and blood pressure decreases. The irreversibility is clinically important: recovery from reserpine's effects requires synthesis of new VMAT2 protein, which takes days to weeks — making reserpine a very long-acting agent with a prolonged offset. VMAT2 blockade also depletes vesicular dopamine and serotonin, explaining reserpine's severe CNS adverse effects: profound depression (from CNS serotonin and dopamine depletion) was a major reason for its clinical abandonment as a first-line antihypertensive.
Option A: Option A incorrectly identifies reserpine's mechanism as calcium channel blockade at nerve terminals. Reserpine does not block calcium channels; its mechanism is intracellular VMAT2 blockade preventing vesicular NE packaging.
Option B: Option B incorrectly identifies reserpine as a postsynaptic alpha-1 receptor blocker. Reserpine acts presynaptically (intraneuronally) to block VMAT2, not postsynaptically to block receptor activation.
Option C: Option C incorrectly identifies reserpine's mechanism as tyrosine hydroxylase inhibition. Reserpine does not inhibit NE synthesis; it prevents vesicular storage of already-synthesized NE. Metyrosine (alpha-methyl-tyrosine) is the drug that inhibits tyrosine hydroxylase.
Option D: Option D incorrectly describes reserpine as an alpha-2 autoreceptor blocker. Reserpine blocks VMAT2, not autoreceptors; the mechanism described would increase rather than deplete NE stores.
5. Tachyphylaxis is a phenomenon in which repeated doses of a drug produce progressively smaller effects. Which of the following best explains why tachyphylaxis occurs more rapidly and more completely with indirect-acting sympathomimetics than with direct-acting adrenergic agonists?
A) Tachyphylaxis with indirect-acting sympathomimetics occurs because repeated exposure induces CYP3A4 in the liver, accelerating metabolic inactivation of the drug; direct-acting agonists are not CYP3A4 substrates and therefore do not undergo the same metabolic acceleration with repeated dosing
B) Tachyphylaxis with indirect-acting sympathomimetics occurs because repeated receptor stimulation by released NE causes GRK-mediated beta-arrestin recruitment and receptor internalization (downregulation), reducing the number of surface receptors available; direct-acting agonists produce the same receptor downregulation at the same rate, so tachyphylaxis occurs equally with both drug classes
C) Tachyphylaxis with indirect agonists is specifically caused by progressive depletion of the vesicular NE store — each dose of an indirect agonist causes NE release from vesicles; the released NE may be partially recovered by reuptake, but repeated releases progressively reduce the net available pool; as the pool shrinks, each subsequent dose releases less NE, and since the entire drug effect depends on the size of this pool, efficacy declines with each dose; direct-acting agonists bypass NE stores entirely (acting at the receptor directly) and therefore do not deplete a finite substrate for their own action
D) Tachyphylaxis with indirect agonists occurs because the drug itself accumulates in the nerve terminal and competitively displaces NE from its vesicular storage sites permanently; the accumulated drug occupies vesicle binding sites, preventing NE replenishment even after synthesis; direct-acting agonists do not accumulate in nerve terminals
E) Tachyphylaxis does not occur with indirect-acting sympathomimetics — the progressive reduction in effect with repeated dosing reflects pharmacokinetic accumulation of inactive metabolites that competitively block adrenergic receptors; direct-acting agonists produce true tachyphylaxis while indirect agonists produce pseudo-tolerance from metabolite accumulation
ANSWER: C
Rationale:
Tachyphylaxis with indirect-acting sympathomimetics is a direct consequence of the pharmacological dependence of this drug class on a finite and slowly replenished vesicular NE pool. Each dose of an indirect agonist (amphetamine, ephedrine, tyramine) triggers NE release from synaptic vesicles. Although some released NE is recovered by NET reuptake back into the terminal, a fraction is lost to COMT and MAO metabolism in the synaptic cleft or taken up by non-neuronal tissues. Repeated doses therefore progressively reduce the net vesicular NE pool. Since indirect agonists have no intrinsic receptor activity — their entire pharmacological effect depends on the NE they can mobilize — a smaller pool produces a smaller effect. This is mechanistically distinct from direct agonists (epinephrine, norepinephrine, phenylephrine, albuterol), which act directly at receptors and do not consume a finite substrate for their own action; while direct agonists can produce receptor downregulation with prolonged exposure, this occurs more slowly and through a different mechanism than the rapid tachyphylaxis seen with indirect agonists.
Option A: Option A incorrectly attributes tachyphylaxis to CYP3A4 induction and metabolic acceleration. Indirect sympathomimetics such as ephedrine and tyramine are not primarily metabolized by CYP3A4; metabolic tolerance is not the mechanism of tachyphylaxis in this drug class.
Option B: Option B incorrectly states that tachyphylaxis occurs equally with direct and indirect agonists through receptor downregulation. While receptor downregulation does occur with prolonged direct agonist use, the rapid tachyphylaxis characteristic of indirect agonists is specifically caused by NE store depletion — a mechanism unique to indirect agonists.
Option D: Option D incorrectly describes drug accumulation in nerve terminals permanently occupying vesicle binding sites. Indirect agonists enter terminals transiently to exchange for NE; they do not permanently occupy vesicular binding sites and do not prevent NE replenishment in this manner.
Option E: Option E incorrectly states that tachyphylaxis does not occur with indirect agonists and that the progressive reduction reflects metabolite accumulation. Tachyphylaxis is well-established and pharmacologically defined for indirect sympathomimetics; it is caused by NE store depletion, not metabolite accumulation.
6. A patient taking phenelzine (an irreversible MAOI — monoamine oxidase inhibitor) for treatment-resistant depression eats a meal containing aged cheese (which is rich in tyramine). Within 30 minutes he develops a severe headache, blood pressure of 210/118 mmHg, diaphoresis, and tachycardia. Using indirect sympathomimetic pharmacology, which of the following best explains the mechanism of this hypertensive crisis?
A) The hypertensive crisis occurs because phenelzine directly activates alpha-1 adrenergic receptors in vascular smooth muscle when combined with tyramine; the combination of an MAOI plus tyramine creates a new pharmacologically active compound through a chemical reaction in the gastrointestinal tract that is more potent than either agent alone; this neosynthesized compound is responsible for the blood pressure elevation
B) Phenelzine irreversibly inhibits intestinal and hepatic MAO, allowing dietary tyramine (normally destroyed by MAO before reaching the systemic circulation) to be absorbed intact; tyramine then acts as an indirect sympathomimetic — entering sympathetic nerve terminals via NET and displacing NE from vesicles through reverse transport; the resulting NE surge activates peripheral adrenergic receptors, causing intense vasoconstriction (alpha-1) and cardiac stimulation (beta-1); simultaneously, intraneuronal MAO is also inhibited, so released NE cannot be degraded intraneuronally — amplifying and prolonging the NE surge; the combined effect produces a hypertensive crisis
C) The crisis occurs because phenelzine inhibits NET (the norepinephrine transporter), and tyramine from food blocks VMAT2; the combined NET and VMAT2 blockade prevents NE clearance from the synapse; the accumulated synaptic NE activates adrenergic receptors producing hypertension; this interaction does not involve NE release, only NE accumulation through dual transporter blockade
D) Tyramine from aged cheese directly activates alpha-1 adrenergic receptors in vascular smooth muscle without requiring NE release; phenelzine potentiates this direct receptor activation by upregulating alpha-1 receptor expression through MAO-independent mechanisms; the crisis results from supranormal alpha-1 receptor density combined with direct tyramine agonism
E) The crisis occurs because phenelzine inhibits the renal clearance of tyramine, causing tyramine to accumulate in the bloodstream to toxic concentrations; tyramine at high plasma concentrations crosses the blood-brain barrier and activates central sympathetic nuclei directly, producing centrally driven hypertension independent of peripheral adrenergic receptor activation
ANSWER: B
Rationale:
The tyramine reaction is one of the most important and dangerous drug-food interactions in clinical pharmacology, and its mechanism is a direct application of indirect sympathomimetic pharmacology. Under normal circumstances, dietary tyramine is efficiently destroyed by MAO in the intestinal wall and liver (first-pass MAO inactivation) before reaching the systemic circulation — so dietary tyramine has no significant hemodynamic effect. When a patient is taking an irreversible MAOI such as phenelzine, tranylcypromine, or isocarboxazid, intestinal and hepatic MAO are inhibited, dramatically reducing the first-pass destruction of dietary tyramine. Tyramine is then absorbed intact into the systemic circulation. Once in the bloodstream, tyramine acts as an indirect sympathomimetic — it is taken up by sympathetic nerve terminals via NET and displaces vesicular NE through reverse transport, flooding the synapse with NE. The simultaneous inhibition of intraneuronal MAO (which normally degrades NE that has been recaptured by the terminal) means that the released and recaptured NE cannot be broken down, amplifying the NE surge. The resulting intense adrenergic activation produces vasoconstriction (alpha-1), hypertension, tachycardia (beta-1), diaphoresis, and severe headache — a potentially fatal hypertensive crisis.
Option A: Option A incorrectly describes the mechanism as a chemical reaction between phenelzine and tyramine producing a new compound. No such reaction occurs; the mechanism is pharmacological (MAO inhibition enabling tyramine absorption and subsequent indirect NE release).
Option C: Option C incorrectly describes phenelzine as a NET inhibitor and tyramine as a VMAT2 blocker. Phenelzine inhibits MAO, not NET; tyramine acts as an indirect agonist releasing NE from vesicles, not as a VMAT2 blocker.
Option D: Option D incorrectly describes tyramine as a direct alpha-1 receptor agonist. Tyramine has negligible direct receptor activity; it is an indirect sympathomimetic that works exclusively through NE release.
Option E: Option E incorrectly attributes the crisis to renal tyramine accumulation and central nervous system activation. The mechanism is peripheral — MAO inhibition allows tyramine to survive intestinal/hepatic first-pass, reach the systemic circulation, and trigger peripheral sympathetic NE release.
7. Tricyclic antidepressants (TCAs — such as amitriptyline, imipramine, and nortriptyline) block NET and can potentiate the effects of directly acting sympathomimetics. However, TCAs reduce the effects of indirectly acting sympathomimetics. Using the mechanism of indirect sympathomimetics, which of the following best explains this paradox?
A) TCAs reduce the effects of indirect sympathomimetics because TCAs also inhibit MAO, competing with MAO inhibitors for the same enzyme; when both TCA and indirect agonist are present, MAO inhibition is incomplete and more tyramine or amphetamine is degraded than expected, reducing the indirect agonist's effect
B) TCAs reduce the effects of indirect sympathomimetics because TCAs block alpha-2 presynaptic autoreceptors, activating the negative feedback loop for NE release; the enhanced alpha-2 autoreceptor-mediated inhibition prevents the indirect agonist from releasing additional NE, counteracting its sympathomimetic effect
C) TCAs potentiate direct sympathomimetics because by blocking NET, they prevent reuptake of directly released NE — prolonging and intensifying the postsynaptic effect; TCAs reduce the effects of indirect sympathomimetics because indirect agonists require entry into the nerve terminal via NET to displace vesicular NE; when NET is blocked by the TCA, the indirect agonist cannot enter the terminal and therefore cannot release NE — the entire indirect mechanism is blocked at its first step
D) TCAs have no effect on indirect sympathomimetics — the reduction in effect described is a pharmacokinetic interaction in which TCAs induce CYP2D6, accelerating the metabolism of indirect agonists such as ephedrine and tyramine; the apparent reduction in sympathomimetic effect is due to lower drug concentrations rather than a mechanistic interaction
E) TCAs reduce the effects of indirect sympathomimetics because TCAs cause massive NE release from all sympathetic terminals upon first administration, depleting the NE stores before the indirect agonist is given; subsequent indirect agonist doses find empty vesicles and cannot release NE; this NE depletion effect is analogous to reserpine pretreatment
ANSWER: C
Rationale:
This question highlights a pharmacologically elegant paradox that follows directly from understanding the mechanism of indirect sympathomimetics. TCAs block NET — the norepinephrine transporter — at the presynaptic membrane. This single molecular action has opposite consequences for direct versus indirect sympathomimetics: For direct sympathomimetics (epinephrine, norepinephrine, phenylephrine): NET blockade prevents reuptake of released NE, prolonging its presence in the synapse and potentiating the postsynaptic adrenergic effect — this is why TCAs can precipitate hypertensive crises when combined with directly acting vasopressors. For indirect sympathomimetics (amphetamine, ephedrine, tyramine): NET is the entry point into the nerve terminal — indirect agonists are transported into the terminal by NET in order to displace vesicular NE. When TCAs block NET, indirect agonists cannot enter the terminal, and the entire indirect mechanism is pharmacologically prevented at its first step. The indirect agonist, unable to enter the terminal, cannot displace NE from vesicles, and NE is not released — the sympathomimetic effect is abolished. This interaction has clinical significance: patients on TCAs who take sympathomimetic medications for nasal congestion (containing ephedrine or phenylephrine) may experience exaggerated responses to phenylephrine (direct) but blunted responses to ephedrine (indirect component of its mixed mechanism).
Option A: Option A incorrectly describes TCAs as MAO inhibitors. TCAs primarily block monoamine transporters (NET, DAT, SERT); they do not inhibit MAO.
Option B: Option B incorrectly attributes the reduction in indirect agonist effects to TCA-mediated alpha-2 autoreceptor blockade. TCAs do not selectively block presynaptic alpha-2 autoreceptors; their primary mechanism is NET (and DAT/SERT) blockade.
Option D: Option D incorrectly attributes the reduction to CYP2D6 induction. TCAs are CYP2D6 substrates but do not significantly induce this enzyme; the interaction with indirect sympathomimetics is pharmacodynamic (NET blockade preventing terminal entry), not pharmacokinetic.
Option E: Option E incorrectly describes TCAs as causing massive NE depletion analogous to reserpine. TCAs block NE reuptake (the opposite of depletion) — they increase synaptic NE by preventing its removal. TCA pretreatment does not deplete NE stores.
8. Reserpine pretreatment abolishes the sympathomimetic effects of indirect-acting agonists but does not abolish the effects of direct-acting agonists. A pharmacologist uses this experimental observation to classify a new drug. After reserpine pretreatment, the new drug produces no hemodynamic response. What does this result indicate about the new drug's mechanism, and what would predict a different result?
A) The absence of hemodynamic response after reserpine pretreatment indicates the new drug is an indirect-acting sympathomimetic that requires intact vesicular NE stores for its effect — reserpine's VMAT2 blockade depletes these stores, removing the substrate on which the new drug depends; if the drug had direct receptor agonist activity, it would have retained at least partial hemodynamic effect after reserpine pretreatment because direct agonists do not require NE stores; a mixed-acting drug (like ephedrine) would show partial loss of effect (losing the indirect component) but retain some effect through its direct component
B) The absence of hemodynamic response after reserpine pretreatment indicates the new drug is a direct-acting sympathomimetic; reserpine depletes postsynaptic adrenergic receptor reserves, and direct agonists require these receptor reserves to produce a response; indirect agonists, which work through NE release rather than receptor binding, are unaffected by reserpine pretreatment; the prediction would be that indirect agonists would still produce a full response after reserpine
C) The absence of response indicates the drug is an adrenergic receptor antagonist; reserpine activates adrenergic receptors constitutively, and when a receptor antagonist is given after reserpine, the constitutive activation is blocked; this manifests as no hemodynamic response; a direct agonist given after reserpine would produce a supranormal response because reserpine upregulates adrenergic receptors
D) The result is uninterpretable because reserpine has non-specific membrane effects that alter receptor conformation for all adrenergic drugs; the hemodynamic response to any adrenergic agent is unreliable after reserpine pretreatment; only drugs with no adrenergic mechanism would produce a hemodynamic response after reserpine
E) The absence of response indicates the drug works through a non-adrenergic mechanism entirely; reserpine has no effect on drugs acting through adrenergic receptors; the absence of response means the drug normally works through monoamine stores in non-adrenergic tissues (mast cells, enterochromaffin cells) that reserpine depletes; direct adrenergic agonists would be unaffected
ANSWER: A
Rationale:
The reserpine pretreatment test is a classic pharmacological tool for classifying sympathomimetic drugs by mechanism. Reserpine irreversibly blocks VMAT2, causing progressive depletion of vesicular NE stores over days. After adequate reserpine pretreatment, vesicular NE stores are exhausted — indirect-acting agonists, which work by displacing and releasing stored vesicular NE, have no substrate to work with and produce no response. Direct-acting agonists, which bind and activate adrenergic receptors without requiring NE stores, retain their full effect after reserpine pretreatment because they bypass the depleted NE stores entirely. Mixed-acting agonists like ephedrine show partial loss of effect — the indirect (NE-releasing) component is abolished, but the direct (receptor-binding) component persists, producing a diminished but not absent response. This test allows pharmacologists to determine: complete abolition of effect = pure indirect agonist; complete preservation of effect = pure direct agonist; partial reduction = mixed-acting agonist. The result for the new drug (no response after reserpine) classifies it as a pure indirect-acting sympathomimetic.
Option B: Option B reverses the experimental prediction — incorrectly stating that reserpine abolishes direct agonist responses and that indirect agonists are unaffected. Reserpine specifically depletes NE stores, abolishing indirect agonist effects while preserving direct agonist effects.
Option C: Option C incorrectly describes reserpine as activating adrenergic receptors constitutively and incorrectly describes the new drug as a receptor antagonist. Reserpine depletes NE stores; it does not activate receptors. A receptor antagonist would reduce (not eliminate) responses to agonists, not produce no response itself.
Option D: Option D incorrectly dismisses the reserpine pretreatment test as uninterpretable. The test is a well-validated pharmacological tool with established and reproducible interpretive criteria; reserpine does not have non-specific membrane effects that confound all adrenergic drug responses.
Option E: Option E incorrectly attributes the absence of response to non-adrenergic monoamine stores. Reserpine depletes monoamine stores in sympathetic nerve terminals specifically; the interpretation of no response in this context is that the drug is a pure indirect sympathomimetic depending on those stores.
9. A student asks: "If cocaine and TCAs both block NET and both prevent NE reuptake, why is cocaine a drug of abuse while TCAs are antidepressants — and why do they have such different clinical profiles despite sharing this mechanism?" Which of the following best answers this question?
A) Cocaine and TCAs have identical clinical profiles when used at equivalent doses — both produce equivalent antidepressant effects and equivalent abuse potential; the different clinical applications of cocaine and TCAs reflect regulatory and social factors rather than pharmacological differences
B) The difference lies entirely in their routes of administration — cocaine is inhaled or insufflated, producing rapid CNS absorption and a fast, intense high; TCAs are taken orally, producing slow absorption; the NET blockade mechanism is identical; route of administration is the sole pharmacological distinction
C) TCAs block NET more selectively than cocaine — TCAs have 100-fold greater NET selectivity over DAT (dopamine transporter) while cocaine blocks NET, DAT, and SERT with more equal potency; the dopamine transporter (DAT) blockade in the nucleus accumbens is the primary driver of cocaine's reinforcing and addictive properties; additionally, cocaine's rapid CNS penetration (lipophilic, small molecule) and rapid onset produce the steep concentration-versus-time gradient in the CNS reward pathway that drives craving and addiction; TCAs' slower onset, longer half-lives, lack of significant DAT blockade, and additional receptor activities (H1, M1, alpha-1 blockade) produce the gradual monoamine enhancement that underlies antidepressant efficacy without meaningful reinforcement
D) The difference is that TCAs are direct-acting adrenergic agonists while cocaine is an indirect-acting agonist; direct agonists have antidepressant properties while indirect agonists have abuse potential; the NET blockade described for TCAs is pharmacologically inaccurate — TCAs work through receptor activation, not transporter blockade
E) Cocaine and TCAs both produce antidepressant effects in clinical trials; the reason cocaine is not used as an antidepressant is purely its short duration of action, which makes it impractical for once-daily dosing; once sustained-release cocaine formulations are developed, it would be equivalent to TCAs as an antidepressant
ANSWER: C
Rationale:
This question addresses a conceptually important comparison that highlights how the same molecular target (NET) can produce radically different clinical outcomes depending on selectivity, pharmacokinetics, and additional pharmacological properties. Both cocaine and TCAs block NET, thereby increasing synaptic NE (and serotonin, in the case of SERT-blocking TCAs). However, several factors distinguish them clinically: (1) Dopamine transporter selectivity — cocaine potently blocks DAT in the nucleus accumbens, the mesolimbic dopamine reward pathway; DAT blockade produces the euphoric reinforcing effect that drives addiction; TCAs have relatively little DAT activity and therefore produce minimal reinforcement in the reward pathway; (2) Pharmacokinetics and onset — cocaine is rapidly CNS-penetrant and has a very short duration of action; the steep, rapid peak in CNS dopamine (from DAT blockade) followed by rapid decline is the pharmacokinetic signature of addictive reinforcement; TCAs have slower onset and much longer half-lives, producing gradual monoamine changes without the sharp pleasure-crash cycle; (3) Additional receptor activities — TCAs block H1 histamine, M1 muscarinic, and alpha-1 adrenergic receptors, producing sedation, anticholinergic effects, and orthostatic hypotension — side effects that limit their abuse potential; cocaine lacks these receptor activities.
Option A: Option A incorrectly states that cocaine and TCAs have identical clinical profiles. Their clinical profiles differ dramatically in terms of abuse potential, reinforcement, antidepressant efficacy, and side effect profiles — differences explained by their pharmacological differences beyond shared NET blockade.
Option B: Option B incorrectly attributes the entire difference to route of administration. While route and pharmacokinetics contribute, the fundamental pharmacological differences (especially DAT selectivity) are more important in explaining the different clinical profiles.
Option D: Option D incorrectly describes TCAs as direct-acting adrenergic agonists and incorrectly states that NET blockade is pharmacologically inaccurate for TCAs. NET blockade is a well-established and primary mechanism of TCAs; they are not direct receptor agonists.
Option E: Option E incorrectly states that cocaine produces antidepressant effects in clinical trials and that the only reason it is not used as an antidepressant is its short duration. Cocaine's high abuse potential, cardiovascular toxicity, and adverse CNS effects preclude its use as an antidepressant regardless of duration; sustained-release formulations would not make it equivalent to TCAs.
10. A 34-year-old woman with treatment-resistant depression has been taking phenelzine 45 mg twice daily for 8 weeks. She develops a mild upper respiratory tract infection and visits a pharmacy for an over-the-counter cold remedy. The pharmacist asks whether she takes any medications. Which of the following combinations of ingredients in an OTC cold remedy would pose the GREATEST risk of a life-threatening interaction in this patient, and what is the mechanism?
A) A cold remedy containing acetaminophen and guaifenesin — acetaminophen is hepatotoxic at high doses and phenelzine induces CYP2E1, increasing acetaminophen's conversion to its toxic NAPQI (N-acetyl-p-benzoquinone imine) metabolite; guaifenesin is an expectorant with no adrenergic activity; the combination risks acetaminophen toxicity but not hypertensive crisis
B) A cold remedy containing pseudoephedrine (an indirect-acting sympathomimetic) and dextromethorphan — pseudoephedrine enters sympathetic nerve terminals via NET, releases NE from vesicles through reverse transport, and produces a massive NE surge in a patient whose intraneuronal MAO is inhibited (phenelzine); the NE surge cannot be degraded intraneuronally, producing intense and prolonged adrenergic activation with risk of hypertensive crisis; dextromethorphan (a serotonin reuptake inhibitor at high doses) in the presence of phenelzine risks serotonin syndrome from combined MAO inhibition and serotonin reuptake blockade — making this combination doubly dangerous
C) A cold remedy containing phenylephrine alone — phenylephrine as a direct alpha-1 agonist would be potentiated by phenelzine because MAO inhibition prevents the degradation of phenylephrine; the combination produces enhanced vasoconstriction at normal phenylephrine doses; this is the greatest risk because direct agonist effects are entirely MAO-dependent
D) A cold remedy containing loratadine (a non-sedating antihistamine) and zinc gluconate — loratadine inhibits histamine H1 receptors and phenelzine upregulates H1 receptor sensitivity; the combination produces paradoxical histamine excess that triggers mast cell degranulation and systemic anaphylaxis; zinc gluconate inhibits MAO independently, adding to phenelzine's MAO inhibition and worsening the risk
E) A cold remedy containing oxymetazoline nasal spray — oxymetazoline is an alpha-2 agonist that is systemically absorbed after nasal application; in the presence of phenelzine, oxymetazoline's alpha-2-mediated central sympatholysis is amplified, producing severe bradycardia and hypotension rather than hypertension; this hypotensive crisis is the greatest risk because MAO inhibition potentiates alpha-2 agonist central effects
ANSWER: B
Rationale:
This bridge question applies tyramine reaction pharmacology to a clinically realistic scenario — a patient on a MAOI encountering OTC cold remedies. The greatest risk is the combination containing pseudoephedrine plus dextromethorphan. Pseudoephedrine is a mixed-acting sympathomimetic (primarily indirect) structurally related to ephedrine — it enters sympathetic nerve terminals via NET and releases NE from vesicles through reverse transport. In a patient whose intraneuronal MAO is irreversibly inhibited by phenelzine, the released NE cannot be degraded after reuptake, amplifying and prolonging the NE surge and risking hypertensive crisis — the same mechanism as the tyramine reaction. Dextromethorphan adds a second dangerous interaction: at the doses in OTC preparations, dextromethorphan has serotonin reuptake inhibitor activity; combined with phenelzine's MAO inhibition (which blocks serotonin degradation), this risks serotonin syndrome — a potentially fatal syndrome of hyperthermia, neuromuscular abnormality, and autonomic instability from excess serotonergic activity. The combination of hypertensive crisis risk (from pseudoephedrine) and serotonin syndrome risk (from dextromethorphan) in an MAOI-treated patient makes this the most dangerous option.
Option A: Option A is incorrect on the key clinical decision: a cold remedy containing acetaminophen and guaifenesin is not the most dangerous option for a patient on phenelzine; while the NAPQI concern from CYP2E1 induction is real, the actual hepatotoxic risk from standard acetaminophen doses (without excessive alcohol or pre-existing liver disease) at normal OTC doses is low; Option C (pseudoephedrine-containing cold remedy) is the most dangerous because it carries both hypertensive crisis risk (indirect sympathomimetic) and potential serotonin syndrome risk (from any DXM component), which are acutely life-threatening.
Option C: Option C incorrectly states that phenylephrine's effects are MAO-dependent and that this represents the greatest risk. Phenylephrine is a direct-acting alpha-1 agonist; MAO does not significantly degrade phenylephrine (it is not a MAO substrate because it lacks the catechol ring and has a meta-hydroxyl rather than the catechol structure); while caution is appropriate with any vasopressor in MAOI patients, phenylephrine is generally considered safer than indirect sympathomimetics in this context.
Option D: Option D incorrectly describes loratadine and zinc as dangerous in MAOI patients through histamine-mediated anaphylaxis and MAO inhibition. Loratadine does not cause mast cell degranulation, and zinc gluconate does not inhibit MAO.
Option E: Option E incorrectly identifies oxymetazoline as the greatest risk and incorrectly describes it as an alpha-2 agonist causing central hypotension in MAOI patients. Oxymetazoline is primarily an alpha-1 and alpha-2 agonist used topically; its systemic absorption from nasal application is minimal; and the hypertensive rather than hypotensive interaction would be the concern with MAOI.
11. A 28-year-old man with narcolepsy is being treated with amphetamine 20 mg daily. After 3 weeks of therapy at this dose, he reports to his physician that the medication is no longer as effective as it was initially — he is experiencing more daytime sleepiness despite taking the medication consistently. His physician confirms there are no changes in his sleep habits, diet, or other medications. Using indirect sympathomimetic pharmacology, which of the following best explains this reduced efficacy?
A) Amphetamine has induced CYP2D6 in the liver over 3 weeks of use, accelerating its own metabolism (autoinduction); the lower plasma concentrations of amphetamine at the same dose explain the reduced CNS stimulant effect; increasing the dose would restore plasma concentrations and efficacy
B) Repeated daily amphetamine dosing progressively depletes the vesicular NE (and dopamine) stores in CNS neurons; each dose releases monoamines from vesicles — while synthesis replenishes stores over time, chronic high-frequency release may outpace replenishment, leaving smaller stores available for each subsequent dose; additionally, GRK-mediated receptor downregulation from repeated adrenergic and dopaminergic stimulation further reduces the response to the released monoamines; the combined effect is reduced monoamine release per dose and reduced receptor sensitivity — both contributing to tachyphylaxis
C) Amphetamine has activated the hypothalamic-pituitary-adrenal (HPA) axis over 3 weeks, causing cortisol hypersecretion that suppresses CNS adrenergic receptor expression; the cortisol-mediated downregulation of adrenergic receptors reduces amphetamine's stimulant effect despite unchanged plasma drug concentrations
D) The reduced efficacy reflects immune tolerance — repeated amphetamine exposure induces formation of anti-amphetamine antibodies after 2–3 weeks; these antibodies neutralize amphetamine in plasma, preventing it from reaching CNS targets; switching to a structurally different stimulant (methylphenidate) would bypass the antibody-mediated neutralization
E) Amphetamine has no mechanism for producing tachyphylaxis at therapeutic doses — the reduced efficacy is explained entirely by psychological tolerance (learned suppression of wakefulness from habit formation); pharmacological dose adjustment is not indicated; cognitive behavioral therapy for sleep hygiene would address the psychological tolerance
ANSWER: B
Rationale:
The reduced efficacy of amphetamine after 3 weeks of use at the same dose illustrates tachyphylaxis — a pharmacological (not psychological) phenomenon. Amphetamine's mechanism is vesicular monoamine displacement and reverse transport, releasing NE and dopamine (in the CNS, dopamine release in the prefrontal cortex and striatum contributes significantly to its stimulant and wakefulness-promoting effects). With repeated daily dosing, the net vesicular monoamine pool is progressively reduced despite ongoing biosynthesis, because release outpaces replenishment — particularly when dosing is frequent. Additionally, chronic adrenergic and dopaminergic receptor stimulation triggers GRK-mediated receptor phosphorylation, beta-arrestin recruitment, and receptor internalization (downregulation), reducing receptor density and sensitivity. The combination of smaller monoamine stores (less drug to release) and fewer/less-sensitive receptors (less response to what is released) produces progressive tachyphylaxis. This is the pharmacological basis for the clinical escalation of stimulant doses seen in long-term amphetamine therapy and the rationale for drug holidays (allowing stores to replenish and receptors to normalize).
Option A: Option A incorrectly attributes the reduced efficacy to CYP2D6 autoinduction. Amphetamine does not significantly induce CYP2D6; pharmacokinetic autoinduction is not the mechanism of tachyphylaxis for this drug class.
Option C: Option C incorrectly attributes the reduced efficacy to HPA axis activation and cortisol-mediated receptor suppression. While amphetamine does activate the HPA axis acutely, this is not the primary mechanism of the progressive tachyphylaxis seen with repeated dosing.
Option D: Option D incorrectly describes immune tolerance through antibody formation against amphetamine. Small molecules like amphetamine do not typically induce antibody formation; immune tolerance is not a mechanism of stimulant tachyphylaxis.
Option E: Option E incorrectly dismisses pharmacological tachyphylaxis and attributes the reduced efficacy entirely to psychological tolerance. Tachyphylaxis to indirect sympathomimetics through monoamine store depletion is a pharmacological phenomenon that occurs independently of psychological factors; pharmacological explanation and management are appropriate.
12. At the end of Module 4, a student summarizes: "The key clinical lesson from indirect-acting sympathomimetics is that their effects are entirely dependent on endogenous NE stores — deplete those stores and the drugs fail." A second student counters: "But the MAOI interaction shows that preserving NE stores beyond normal can be equally dangerous." Which of the following best synthesizes these two observations into a unifying clinical pharmacology principle for indirect-acting sympathomimetics?
A) The two observations cannot be reconciled because they represent contradictory pharmacological phenomena — depletion of NE stores reducing drug effect and preservation of NE stores increasing drug effect cannot both be explained by the same mechanism; they reflect different receptor populations responding to the same drug class
B) Both observations are explained by the same underlying principle: the magnitude of the indirect sympathomimetic effect is directly proportional to the size of the available vesicular NE pool — when stores are depleted (reserpine), effects are abolished; when stores are preserved and amplified beyond normal (MAO inhibition preventing NE degradation), the NE released by an indirect agonist produces a massively amplified and potentially catastrophic adrenergic response; the NE store is the pharmacological amplifier for indirect agonists, and its size determines both the floor (no stores = no effect) and the ceiling (augmented stores = supranormal, dangerous effect) of indirect sympathomimetic pharmacology
C) The two observations are reconciled by noting that different indirect sympathomimetics have different mechanisms — drugs that work by NE depletion (reserpine) are abolished by reserpine pretreatment while drugs that work by MAO inhibition are potentiated by MAOI co-administration; the student's summary applies only to one subclass of indirect agonists
D) The unifying principle is that indirect sympathomimetics are inherently unpredictable drugs whose effects cannot be reliably titrated; their dependence on NE stores and the variability of NE stores between patients makes them unsuitable for clinical use in any setting where precise dose-response control is needed; both observations reflect the fundamental unreliability of indirect pharmacology
E) Both observations reflect the same phenomenon — receptor upregulation; when NE stores are depleted, adrenergic receptors upregulate (increasing sensitivity to any remaining NE or direct agonist), producing paradoxical enhancement; when MAO is inhibited, receptor upregulation from excess NE stimulation produces paradoxical hypersensitivity; indirect sympathomimetics trigger receptor changes regardless of NE store size
ANSWER: B
Rationale:
This integrative closing question synthesizes the key pharmacological principle of the entire module. Both observations — store depletion abolishing indirect agonist effect, and MAOI-mediated store amplification producing dangerous hyperstimulation — are explained by the same underlying principle: the vesicular NE pool functions as the pharmacological amplifier for indirect-acting sympathomimetics. The magnitude of an indirect sympathomimetic effect is determined by the size of the NE pool available for release: When stores are depleted (by reserpine blocking VMAT2), there is no NE to release and the indirect agonist's effect is abolished — the drug is pharmacologically silenced. When stores are preserved and amplified beyond normal (by MAO inhibition preventing intraneuronal NE degradation, combined with dietary tyramine or exogenous indirect agonist), the NE released per dose far exceeds what would normally occur — producing a supranormal, potentially catastrophic adrenergic surge. The NE store thus defines both the minimum (floor: depleted stores = no effect) and maximum (ceiling: augmented stores = dangerous excess) of indirect sympathomimetic pharmacology. This principle — that indirect drugs are amplifiers of the endogenous NE pool whose clinical effect scales with pool size — is the unifying concept connecting tachyphylaxis, reserpine pretreatment experiments, the tyramine reaction, and the clinical unpredictability of indirect sympathomimetics in patients with altered NE metabolism.
Option A: Option A incorrectly states the two observations are contradictory and irreconcilable. They are in fact two ends of the same pharmacological spectrum — both explained by the relationship between NE store size and indirect agonist effect magnitude.
Option C: Option C incorrectly describes reserpine as an indirect sympathomimetic. Reserpine is an adrenergic neuron blocker that depletes NE stores — it is the pretreatment tool used to test indirect agonists, not an indirect agonist itself.
Option D: Option D incorrectly characterizes indirect sympathomimetics as inherently unpredictable and unsuitable for clinical use. While their NE-store dependence introduces some variability, indirect sympathomimetics are used clinically (ephedrine in anesthesia, pseudoephedrine as decongestant); the principle is not clinical unsuitability but rather understanding the determinants of their effect magnitude.
Option E: Option E incorrectly attributes both observations to receptor upregulation. While receptor upregulation does occur after prolonged NE depletion (supersensitivity), this is not the mechanism explaining why MAO inhibition potentiates indirect sympathomimetics; the MAOI interaction is explained by NE pool amplification, not receptor upregulation.
BEFORE YOU MOVE ON
Module 4 has established the pharmacological principles governing indirect-acting and mixed sympathomimetics — drug classes defined by their dependence on endogenous NE stores and characterized by tachyphylaxis, NE-pool-dependent effect magnitude, and clinically critical drug interactions. The unifying principle: the vesicular NE pool is the pharmacological amplifier for indirect agonists, and anything that modifies pool size (reserpine depleting it, MAO inhibitors augmenting it, repeated dosing depleting it progressively) directly modifies the clinical effect. The tyramine reaction and TCA interaction are not obscure pharmacological curiosities — they are real, life-threatening clinical events grounded in the mechanism you now understand. Modules 5 and 6 complete Chapter 5 with the adrenergic antagonists — alpha blockers and beta blockers — where you will apply the receptor framework from Module 1 to understand how blocking rather than activating adrenergic receptors is equally rich in pharmacological and clinical consequence.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.